Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations – second line therapy

featured image
Indications: Urothelial cancer
Therapeutic Areas: Urological Cancer
Year: 2017

Urothelial cancer (UC), is a type of cancer of the urinary system (which includes the bladder and surrounding space). Bladder cancer is the most common type of UC, making up the majority of UC cases. Your risk of getting UC can be increased by smoking, damage to the urinary system (like kidney stones or infections) and having a family history of UC.
Changes to a certain gene, the FGFR gene, has been found in one to two thirds of people with UC. Erdafitinib capsules are a new drug which work by killing cancer cells which have changes to the FGFR gene. It is currently being tested in clinical trials for a range of different cancers, including cancers of the urinary system. If Erdafitinib was licenced for use in the UK it would provide a treatment option for people with late stage or difficult to treat urinary tract cancer with abnormal FGFR gene.